Challenger Ltd just reported even more growth

Challenger Ltd (ASX:CGF) reported its result for the half-year to 31 December 2017.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Challenger Ltd (ASX: CGF) has just reported its result for the six months to 31 December 2017.

Challenger is Australia's leading annuity provider with a dominant market share, below are highlights of its results compared to the prior corresponding period.

The headline figure for Challenger is that group assets under management (AUM) increased by 18% to $76.5 billion. Life AUM increased by 17% and funds under management (FUM) increased by 18%.

Challenger removes the investment performance of its assets and liabilities to produce 'normalised' profit figures.

Normalised net profit before tax (NPBT) increased by 8%, it increased by 13% if the one-off Life Risk fee is excluded. Normalised net profit after tax (NPAT) increased by 6%, it increased by 10% if the one-off Life Risk fee is excluded. The higher effective tax rate hurt the NPAT figure.

The statutory NPAT decreased by 3% due to the negative investment experience of $17 million.

Normalised pre-tax return on equity (ROE) dipped to 16.8% and was below the 18% target. However, Challenger said this was expected as it currently has higher levels of capital after the MS&AD placement in August 2017.

The AUM and normalised profit growth figures were driven up by the ever-increasing annuity sales. 'Life' sales were up 21% to $3.3 billion, annuity sales were up 4% and 'Other Life' sales were up 84% to $1 billion.

Long-term annuity sales were up 20%, which represents 'Lifetime' and MS Primary annuities. Long-term annuity sales made up 36% of total annuity sales, Lifetime represented 19% of annuity sales and MS Primary represented 17%.

The dividend increased by 3% to 17.5 cents per share and is fully franked. The dividend payout ratio is 49.7% and the overall cash payout is expected to be reduced by 2% due to the dividend re-investment plan.

Outlook

Challenger re-iterated its FY18 profit guidance of normalised net profit before tax of between $545 million to $565 million, which represents growth of between 8% to 12%.

The company expects to achieve its 18% return on equity target in the medium-term, but FY18 (and perhaps beyond) will be impacted until the higher levels of capital are fully deployed.

Management will maintain the normalised NPAT dividend payout ratio of 45% to 50%.

Foolish takeaway

Overall, I thought this was a solid result from Challenger. The moves it's making to increase its distribution channels should help long-term profit and profit margins because of how scalable the business is.

The fall in statutory profit was slightly disappointing with almost all asset prices at all-time or multi-year highs at the end of December. As long as Challenger's long-term investment experience shows growth then it's not an issue.

Personally, I was pleased with Challenger's result and I'm glad that it's one of my biggest holdings. I will likely buy more shares if any opportunities present themselves to buy more at a discounted price if market volatility hurts the share price.

Motley Fool contributor Tristan Harrison owns shares of Challenger Limited. The Motley Fool Australia owns shares of and has recommended Challenger Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »